References1. Baumgarten MN, Polanski LT. Modern management of fibroids.Obstet Gynaecol Reprod Med . 2020;30(4):104-108.2. Cruz MSDD La, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment.Am Fam Physician . 2017;95(2):100-107.3. Friend DR. Drug delivery for the treatment of endometriosis and uterine fibroids. Drug Deliv Transl Res . 2017;7(6):829-839.4. Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol . 2018;46:3-11.5. Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: A potential target for future therapeutics. Hum Reprod Update . 2018;24(1):59-85.6. Chwalisz K, Taylor H. Current and Emerging Medical Treatments for Uterine Fibroids. Semin Reprod Med . 2017;35(06):510-522.7. Styer AK, Rueda BR. The Epidemiology and Genetics of Uterine Leiomyoma. Best Pract Res Clin Obstet Gynaecol . 2016;34:3-12.8. McWilliams MM, Chennathukuzhi VM. Recent Advances in Uterine Fibroid Etiology. Semin Reprod Med . 2017;35(2):181-189.9. Donnez J, Courtoy GE, Dolmans MM. Fibroid management in premenopausal women. Climacteric . 2019;22(1):27-33.10. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynecol Obstet . 2020;149(1):3-9.11. Fortin C, Flyckt R, Falcone T. Alternatives to hysterectomy: The burden of fibroids and the quality of life. Best Pract Res Clin Obstet Gynaecol . 2018;46:31-42.12. Harrington A, Bonine NG, Banks E, et al. Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids. J Manag Care Spec Pharm . 2020;26(1l):2-10.13. Zupi E, Centini G, Sabbioni L, Lazzeri L, Argay IM, Petraglia F. Nonsurgical Alternatives for Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol . 2016;34:122-131.14. Manyonda I, Belli AM, Lumsden MA, et al. Uterine-Artery Embolization or Myomectomy for Uterine Fibroids. N Engl J Med . 2020;383(5):440-451.15. Masciocchi C, Arrigoni F, Ferrari F, et al. Uterine fibroid therapy using interventional radiology mini-invasive treatments: current perspective. Med Oncol . 2017;34(4):1-12.16. Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health . 2014;6:95-114.17. Piriyev E, Schiermeier S, Bends R, Römer T. Transcervical radiofrequency ablation of fibroids that are 5 cm or larger in women with abnormal uterine bleeding. J Gynecol Obstet Hum Reprod . 2022;51(2):1-4.18. Faustino F, Martinho M, Reis J, Águas F. Update on medical treatment of uterine fibroids. Eur J Obstet Gynecol Reprod Biol . 2017;216:61-68.19. Sinai Talaulikar V. Medical therapy for fibroids: An overview.Best Pract Res Clin Obstet Gynaecol . 2018;46:48-56.20. Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: An update on current and emerging medical treatment options.Ther Clin Risk Manag . 2019;15:157-178.21. Mas A, Tarazona M, Dasí Carrasco J, Estaca G, Cristóbal I, Monleón J. Updated approaches for management of uterine fibroids. Int J Womens Health . 2017;9:607.22. Lewis TD, Malik M, Britten J, San Pablo AMA, Catherino WH. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. Biomed Res Int . 2018;2018:1-11.23. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol . 2016;214(1):31-44.24. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery. N Engl J Med . 2012;366(5):409-420.25. Ali M, Al-Hendy A. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol . 2018;14(9):887-889.26. Frascà C, Arena A, Degli Esposti E, et al. First Impressions Can Be Deceiving: Surgical Outcomes of Laparoscopic Myomectomy in Patients Pretreated with Ulipristal Acetate. J Minim Invasive Gynecol . 2020;27(3):633-638.27. Ciebiera M, Ali M, Prince L, et al. The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids. J Clin Med 2020, Vol 9, Page 1479 . 2020;9(5):1479.28. Arip M, Yap VL, Rajagopal M, Selvaraja M, Dharmendra K, Chinnapan S. Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review. Front Pharmacol . 2022;13.29. Kamal DAM, Salamt N, Zaid SSM, Mokhtar MH. Beneficial Effects of Green Tea Catechins on Female Reproductive Disorders: A Review.Molecules . 2021;26(9).30. Zhang D, Al-Hendy M, Richard-Davis G, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol . 2010;202(3):1-18.31. Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt) . 2018;27(11):1359-1367.32. Dolmans MM, Donnez J, Fellah L. Uterine fibroid management: Today and tomorrow. J Obstet Gynaecol Res . 2019;45(7):1222-1229.33. Zhang J, Nie S, Wang S. Nanoencapsulation Enhances Epigallocatechin-3-Gallate Stability and Its Anti-atherogenic Bioactivities in Macrophages. J Agric Food Chem . 2013;61(38):9200-9209.34. Alexander A, Ajazuddin, Patel RJ, Saraf S, Saraf S. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release . 2016;241:110-124.35. Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev . 2018;2018(4).36. Moravek MB, Bulun SE. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. Curr Opin Obstet Gynecol . 2015;27(4):276-283.37. Ekanem E, Talaulikar V. Medical Therapy for Fibroids: What Next for Ulipristal Acetate? Adv Ther . 2021;38(1):137-148.38. Donnez J, Dolmans MM. Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist. Fertil Steril . 2020;114(4):739-741.39. Neri M, Melis GB, Giancane E, et al. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data. Int J Womens Health . 2019;11:535.40. Ciebiera M, Łukaszuk K, Męczekalski B, et al. Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review. Int J Mol Sci . 2017;18(12).41. Tsuiji K, Takeda T, Li B, et al. Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecol Endocrinol . 2011;27(7):512-517.42. Chen X, Chen X, Shi X, Gao Z, Guo Z. Curcumin attenuates endothelial cell fibrosis through inhibiting endothelial–interstitial transformation. Clin Exp Pharmacol Physiol . 2020;47(7):1182-1192.43. Cetin E, Al-Hendy A, Ciebiera M. Non-hormonal mediators of uterine fibroid growth. Curr Opin Obstet Gynecol . 2020;32(5):361.44. Wu HL, Chuang TY, Al-Hendy A, Diamond MP, Azziz R, Chen YH. Berberine inhibits the proliferation of human uterine leiomyoma cells.Fertil Steril . 2015;103(4):1098-1106.45. Salehi B, Mishra AP, Nigam M, et al. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines . 2018;6(3).46. Wu CH, Shieh TM, Wei LH, et al. Resveratrol inhibits proliferation of myometrial and leiomyoma cells and decreases extracellular matrix-associated protein expression. J Funct Foods . 2016;23:241-252.47. Chen HY, Lin PH, Shih YH, et al. Natural antioxidant resveratrol suppresses uterine fibroid cell growth and extracellular matrix formation in vitro and in vivo. Antioxidants . 2019;8(4):1-16.48. Roshdy E, Rajaratnam V, Maitra S, Sabry M, Ait Allah AS, Al-Hendy A. Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health . 2013;5(1):477-486.49. Puligundla P, Mok C, Ko S, Liang J, Recharla N. Nanotechnological approaches to enhance the bioavailability and therapeutic efficacy of green tea polyphenols. J Funct Foods . 2017;34:139-151.50. Aras A, Khokhar AR, Qureshi MZ, et al. Targeting cancer with nano-bullets: curcumin, EGCG, resveratrol and quercetin on flying carpets. Asian Pac J Cancer Prev . 2014;15(9):3865-3871.51. Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia . 2010;81(7):680-689.52. Singh RP, Gangadharappa H V., Mruthunjaya K. Phospholipids: Unique carriers for drug delivery systems. J Drug Deliv Sci Technol . 2017;39:166-179.53. Zagury Y, Kazir M, Livney YD. Improved antioxidant activity, bioaccessibility and bioavailability of EGCG by delivery in β-lactoglobulin particles. J Funct Foods . 2019;52:121-130.54. Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials . 2018;156:217-237.55. Zare-Zardini H, Ferdowsian F, Soltaninejad H, et al. Application of nanotechnology in biomedicine: A major focus on cancer therapy. J Nano Res . 2015;35:55-66.56. Dewi MK, Chaerunisaa AY, Muhaimin M, Joni IM. Improved Activity of Herbal Medicines through Nanotechnology. Nanomater 2022, Vol 12, Page 4073 . 2022;12(22):4073.57. Rafique S, Segars JH, Leppert PC. Mechanical Signaling and Extracellular Matrix in Uterine Fibroids. Semin Reprod Med . 2017;35(6):487-493.58. Leppert PC, Jayes FL, Segars JH. The Extracellular Matrix Contributes to Mechanotransduction in Uterine Fibroids. Obstet Gynecol Int . 2014;2014:1-12.59. Ali H, Kilic G, Vincent K, Motamedi M, Rytting E. Nanomedicine for Uterine Leiomyoma Therapy. Ther Deliv . 2013;4(2):161.60. Borahay MA, Vincent KL, Motamedi M, et al. Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model. Reprod Sci . 2021;28(1):271-277.61. Shalaby SM, Khater MK, Perucho AM, et al. Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril . 2016;105(6):1638-1648.62. Sadeghi-Goughari M, Jeon S, Kwon HJ. Magnetic nanoparticles-enhanced focused ultrasound heating: size effect, mechanism, and performance analysis. Nanotechnology . 2020;31(24).